Top Aortic Stent Grafts Companies

Aortic Stent Grafts Market size was valued at USD 2.65 Billion in 2023 and is poised to grow from USD 2.76 Billion in 2024 to USD 0 Billion by 2032, growing at a CAGR of 4% during the forecast period (2025-2032).

The competitive landscape for the global aortic stent grafts market is fragmented owing to the presence of multiple vendors. Most players are making heavy investments on R&D, and new market initiatives to gain a competitive edge and attract high revenues. Other vendors are focusing on increasing their global presence, production sites and facilities, production capacities, company strengths and weaknesses, and on new product launches to ensure their brand name stays amongst the top competitors. 'Medtronic Plc', 'Cook Medical Inc.', 'Endologix Inc.', 'W.L. Gore & Associates Inc.', 'Terumo Corporation', 'Lombard Medical Technologies', 'MicroPort Scientific Corporation', 'Merit Medical Systems Inc.', 'JOTEC GmbH', 'CryoLife Inc.', 'Lifetech Scientific (Shenzhen) Co. Ltd.', 'Becton, Dickinson and Company', 'Endospan Ltd.', 'Cardinal Health Inc.', 'MicroVention Inc.', 'Aptus Endosystems Inc.', 'Altura Medical Inc.', 'Penumbra Inc.', 'Biomerics LLC', 'Lombardi SA', 'In November 2023, TekniPlex Healthcare signed a definitive purchase agreement to acquire Seisa Medical, a full solution, complex manufacturing partner, and leader in AAA stent manufacturing. ', 'In September 2022, Getinge AB reported a partnership with Medtronic plc for the Radiant stent, the first covered stent indicated for chimney endovascular aneurysm repair (ChEVAR). This new balloon-expandable stent graft for renal arteries obtained CE mark approval on Sept. 20.'

The market for aortic stent grafts is anticipated to grow during the forecast period due to factors such as the adoption of endovascular repair over open surgical repair, growing life expectancy rate, the increasing use of minimally invasive surgeries, surge in number of clinical trials, and FDA approvals for the development of better aortic stent graft designs.

The market for aortic aneurysm stent grafts is anticipated to grow rapidly as a result of an ageing population and an increase in patients with aortic aneurysms, increased regulatory approvals, and quickening technological development efforts. The market will expand from 2023 to 2030 due to a rise in the prevalence of cardiac disorders and rising consumer awareness of stents and graph devices.

The market for aortic aneurysm stent grafts is anticipated to be dominated by North America. This is attributable to the rising aortic aneurysm cases, technological improvements, and robust financial incentives in the United States and Canada. Additionally, the increasing use of aortic aneurysm stent grafts in the nation will increase demand for therapies that incorporate them, thus, fostering a favourable environment for the expansion of the North American aortic aneurysm stent graft market.